Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease

/in ,

DUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including […]

Read more

AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification

/in

First cGMP-certified manufacturing facility commissioned to manufacture bacteriophage products for human use. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 3, 2014 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana, Slovenia, was […]

Read more

Rex Bionics – First Patient Treated in RAPPER II Clinical Trial

/in ,

1 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce that the first patient has been successfully treated in its RAPPER II (“Robot-Assisted PhysiotheraPy Exercises with REX”) clinical trial. Link here. A 37 year-old male with a spinal cord injury at level T3, […]

Read more

Rex Bionics – Audited Results period ended 31 Mar 2015

/in ,

29 May 2015, Rex Bionics Plc (AIM: RXB) the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces its audited results for the sixteen month period ending 31 March 2015. Link here.

Read more

AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results

/in

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, May 19 2015 Link here. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015. Corporate Update • […]

Read more

Nexvet Appoints Dr. Jurgen Horn as Chief Product Development Officer

/in ,

DUBLIN, Ireland and MELBOURNE, Australia, May 11, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role at Nexvet in August 2015. Dr. Horn most […]

Read more

Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2015

/in ,

DUBLIN, Ireland and MELBOURNE, Australia, May 8, 2015 (GLOBE NEWSWIRE) — Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and nine month periods ended March 31, 2015. Link here. Corporate Highlights In February 2015, we closed our initial public offering of 4.0 million ordinary shares at a price to […]

Read more

SeaDragon appoints Chairman

/in ,

SEA: NZX MARKET UPDATE 8 May 2015 Link here. SeaDragon appoints Chairman with strong international market expertise SeaDragon, New Zealand’s largest refiner and blender of high quality, fish oils and fractions, including Omega 3 oils, is pleased to announce it has appointed Colin Groves as Chairman. Mr Groves has spent the past 23 years primarily as Director […]

Read more

Leadership changes at SeaDragon

/in ,

SEA: NZX MARKET UPDATE 4 May 2015. Link here. New Zealand’s largest refiner and blender of high-quality internationally-certified concentrated fish oils and fractions SeaDragon today advises it has begun a transition to new leadership. As foreshadowed at last year’s AGM, SeaDragon Chairman Dr Doug Wilson has advised the company he wishes to stand down from the […]

Read more

AmpliPhi Biosciences Announces M. Scott Salka as New CEO

/in

Link here. Biotechnology entrepreneur brings extensive business development and fundraising expertise to leading bacteriophage-based antibacterials company. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, April 30, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Scott Salka has been appointed […]

Read more